| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Isotope-labeled galactosylsphingosine; no intrinsic receptor or enzyme agonist activity. Endogenous psychosine is a cytotoxic lipid whose accumulation in Krabbe disease is thought to mediate oligodendrocyte death and demyelination; it is also a substrate for GALC. The deuterated standard is used as an analytical surrogate and does not modulate GALC activity or psychosine-mediated cytotoxicity.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a matter for concern [3].
The d7-psychosine standard shows no intrinsic bioactivity and is not used for potency screening. Endogenous psychosine is a low-abundance cytotoxic lipid that requires a structurally matched internal standard for accurate quantification; the d7 form co-elutes with the analyte and corrects for extraction recovery, ionization efficiency, and matrix effects in dried blood spots, plasma, and tissue. |
| ln Vivo |
No intrinsic in vivo pharmacological activity has been reported for the deuterated standard. Endogenous psychosine accumulates in the central and peripheral nervous systems of patients and animal models with Krabbe disease and is a pharmacodynamic biomarker for GALC enzyme replacement and gene therapy. The d7 standard supports in vivo quantification of psychosine in blood and tissue and enables monitoring of treatment response.
|
| Enzyme Assay |
LC-MS/MS psychosine quantification: add Psychosine-d7 to the sample (e.g., dried blood spot, plasma, or tissue homogenate) before protein precipitation or lipid extraction; extract with methanol or methanol/water; separate on a reversed-phase C18 column or a HILIC column; monitor the specific m/z transition of the d7 standard (e.g., m/z 467.4→289.3) and the corresponding unlabeled psychosine transition (e.g., m/z 460.4→282.3). Quantification is by isotope-dilution calibration using peak-area ratios.
|
| Cell Assay |
Cell-based psychosine cytotoxicity assay: culture oligodendrocyte-lineage cells or Schwann cells, treat with serially diluted psychosine in the presence or absence of GALC, and measure cell viability by MTT or LDH release; quantify psychosine levels in cells and medium by LC-MS/MS using the d7 standard. The assay is used to study psychosine-mediated cytotoxicity and the protective effect of GALC.
|
| Animal Protocol |
In vivo biomarker analysis in Krabbe disease models: collect dried blood spots or tissue (brain, sciatic nerve) from GALC-deficient mice or patients, add Psychosine-d7 as internal standard, extract psychosine, and quantify by LC-MS/MS. The data are used to correlate psychosine levels with disease severity and to monitor the pharmacodynamic effect of enzyme replacement or gene therapy.
|
| References |
|
| Molecular Formula |
C24H40D7NO7
|
|---|---|
| Molecular Weight |
468.68
|
| Exact Mass |
468.379
|
| CAS # |
2315262-31-6
|
| Related CAS # |
Psychosine;2238-90-6
|
| PubChem CID |
164516806
|
| Appearance |
White to off-white solid
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
32
|
| Complexity |
479
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])CCCCCCCCCC/C=C/[C@H]([C@H](CO[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)N)O
|
| InChi Key |
HHJTWTPUPVQKNA-RMWPRCMXSA-N
|
| InChi Code |
InChI=1S/C24H47NO7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(27)18(25)17-31-24-23(30)22(29)21(28)20(16-26)32-24/h14-15,18-24,26-30H,2-13,16-17,25H2,1H3/b15-14+/t18-,19+,20+,21-,22-,23+,24+/m0/s1/i1D3,2D2,3D2
|
| Chemical Name |
(2R,3R,4S,5R,6R)-2-[(E,2S,3R)-2-amino-16,16,17,17,18,18,18-heptadeuterio-3-hydroxyoctadec-4-enoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1337 mL | 10.6683 mL | 21.3365 mL | |
| 5 mM | 0.4267 mL | 2.1337 mL | 4.2673 mL | |
| 10 mM | 0.2134 mL | 1.0668 mL | 2.1337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
